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Aged garlic extract (AGE) is an odorless garlic preparation containing S-allylcysteine (SAC) as its most abundant compound. A
large number of studies have demonstrated the antioxidant activity of AGE and SAC in both in vivo—in diverse experimental
animal models associated to oxidative stress—and in vitro conditions—using several methods to scavenge reactive oxygen species
or to induce oxidative damage. Derived from these experiments, the protective eﬀects of AGE and SAC have been associated with
the prevention or amelioration of oxidative stress. In this work, we reviewed diﬀerent antioxidant mechanisms (scavenging of free
radicals and prooxidant species, induction of antioxidant enzymes, activation of Nrf2 factor, inhibition of prooxidant enzymes,
and chelating eﬀects) involved in the protective actions of AGE and SAC, thereby emphasizing their potential use as therapeutic
agents. In addition, we highlight the ability of SAC to activate Nrf2 factor—a master regulator of the cellular redox state. Here,
we include original data showing the ability of SAC to activate Nrf2 factor in cerebral cortex. Therefore, we conclude that the
therapeutic properties of these molecules comprise cellular and molecular mechanisms at diﬀerent levels.
1.Introduction
Garlic(Alliumsativum)hasbeencultivatedandusedforculi-
nary and medicinal purposes by many cultures for centuries
[1,2].Eventoday,garlicclovesarecommonlyusedinEastern
Europe and Asia, whereas garlic supplements are popular in
Western Europe and growing in popularity in the US. Garlic
is a source particularly rich in organosulfur compounds,
which are responsible for its ﬂavor, aroma, and potential
health beneﬁts [3]. Recent studies have demonstrated and
validated many of the medicinal properties attributed to
garlic [4]. Diﬀerent types of garlic supplements are com-
mercially available, including garlic powders (tablets), garlic
oils (capsules), and aged garlic extracts (tablets, capsules,
and liquid); each of these sources provide a diﬀerent proﬁle
of organosulfur compounds [5]. One of the better known
garlic preparations is aged garlic extract (AGE), which is
formed during garlic aging (up to 20 months). During
this time, unstable and highly odorous compounds in fresh
garlic are converted into more stable and much less odorous
compounds [6].
A considerable number of in vivo and in vitro studies
have been performed so far in order to test the antioxidant
propertiesofAGEandoneofitsmostabundantorganosulfur
compounds, S-allylcysteine (SAC). In these studies, diﬀerent
antioxidant mechanisms have been reported, such as their
ability to (1) scavenge reactive oxygen (ROS) and nitrogen
(RNS) species; (2) increase enzymatic and nonenzymatic2 Oxidative Medicine and Cellular Longevity
antioxidants levels; (3) activate Nrf2 factor; or (4) inhibit
some prooxidant enzymes (xanthine oxidase, cyclooxyge-
nase, and NADPH oxidase).
Given that SAC is the most abundant compound in
AGE, the present paper brings special attention to the
physicochemical characteristics, toxicity, pharmacokinetics,
tissue distribution, and metabolism of this compound, as
well as on the diﬀerent antioxidant mechanisms involved
in its protective actions in diﬀerent experimental models of
toxicity.
2.Aged GarlicExtract(AGE)
AGE is an odorless product resulting from prolonged
extraction of fresh garlic at room temperature; it is highly
bioavailable and exerts biological activity in both animals
and humans. In AGE, garlic (in 15–20% ethanol) is aged for
up to 20 months in stainless steel tanks. The extract is then
ﬁltered and concentrated at low temperature [6]. AGE is sold
in both dry form and as a liquid containing 10% ethanol [4].
The process of aging gently modiﬁes harsh and irritating
compounds from the raw garlic and naturally generates
unique and beneﬁcial compounds through both enzymatic
and natural chemical reactions (Table 1)[ 7]. The main
changes in AGE during aging process are indicated as follows
[4]:
(1) complete hydrolysis of the γ-glutamylcysteines to
SAC and S-1-propenylcysteine (the content of SAC
remains constant after 3 months, but S-1-propeny-
lcysteine steadily decreases);
(2) increase in cystine due to protein hydrolysis and
increase in S-allylmercaptocysteine probably due to
the reaction of allicin with protein derived cysteine;
(3) initial loss of alliin to thiosulﬁnates formation (alli-
cin);
(4) complete loss of thiosulﬁnates after 3 months due
to the fact that they are converted into volatile
allyl sulﬁdes (diallyl sulﬁde, diallyl disulﬁde, diallyl
trisulﬁde), which evaporate almost completely.
Based on typical total SAC content in cloves (41μmole/g
dry wt.), the total SAC content in commercial aged extracts
(7.8μmole/g dry wt. after correcting for 40% excipients)
is only 19%, indicating considerable manufacturing losses
or the use of cloves with an unusually low content of γ-
glutamylcysteines. The commercial aged products are stan-
dardized on SAC content, but a speciﬁc or even minimum
amount has not been declared yet [4].
Recently, new compounds, such as tetrahydro-beta-
carbolines (1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-
carboxylic acid and 1-methyl-1,2,3,4-tetrahydro-beta-car-
boline-1,3-dicarboxylic acid) as well as Nα-(1-deoxy-D-
fructos-1-yl)-L-arginine, have also been identiﬁed in AGE.
These compounds increase during the aging process and
play an important role as antioxidants [8–10]. Indeed,
tetrahydro-beta-carbolines are biologically active alkaloids
and are structurally similar to ﬂavonoids. Nα-(1-deoxy-D-
fructos-1-yl)-L-arginine is only found in AGE and no other
garlic products.
Substantial evidence shows that AGE ameliorates the
oxidative damage implicated in aging and a variety of
diseases, such as cardiovascular alterations, cancer, stroke,
Alzheimer’s disease (AD), and other age-related degenerative
conditions. In addition, AGE is a commercially available
garlic preparation that has been widely studied for its high
antioxidant content and its health-protective potential [11–
17].
3.S-Allylcysteine(SAC):A Key Compound in
Aged GarlicExtract
SAC is formed from γ-glutamyl-S-allylcysteine catabolism
(Figure 1)andhasbeenusedtostandardizecommercialAGE
[7]. SAC is a white crystalline powder with characteristic
odor, it has not hygroscopic ability, and its melting point
is 223.3–223.7◦C[ 18] .S A Ci sas t a b l ec o m p o u n da si t
r e m a i n su n a l t e r e di nA G Ef o ru pt o2y e a r s[ 4]. Stored
crystal samples show a slight change into a yellowish color,
but no transformation or decomposition is observed. Under
basic conditions (2N NaOH, 50◦C, 6 days), allylmercaptan
and allylsulﬁde (decomposition products) are observed,
suggesting that the C–S bond cleavage occurs. However,
under acidic conditions (6N HCl, 50◦C, 5 days), evidence
of C–S bond cleavage is not observed. These observations
indicate that SAC can be absorbed in gastrointestinal tract
after oral administration without any changes [18].
3.1. Toxicity. SAC is 30-fold less toxic than other typical
garlic compounds such as allicin and diallyldisulﬁde. The
50% lethal oral dose (LD50)o fS A Ci nf e m a l e( 9 . 3 9 g / k g )
or male (8.89g/kg) mice was higher than allicin (female:
0.363g/kg and male: 0.309g/kg) and diallyldisulﬁde (female:
1.3g/kg and male: 0.145g/kg) (Reviewed in [6]). Others
studies have conﬁrmed the low toxicity of SAC in male mice,
since LD50 by oral administration was 8.8g/kg (Table 2).
In male rats, LD50 of SAC by i.p. administration (3.34g/kg
(<20mM)) is similar to essential L-amino acids such as
methionine (29mM/kg). Gender diﬀerences were observed
in acute toxicity tests in mice, since LD50 in males was about
1.7 times higher than in females [18].
Negative eﬀects of SAC were observed at high doses
(≥500mg/kg for 1 month, orally) including [18]
(1) decrease of body weight in both genders;
(2) increase of urinary pH in male;
(3) decrease of urinary protein (in female) and uro-
bilinogen (in male) levels. Urobilinogen is a metabo-
lite of bilirubin generated by intestinal bacteria that
is reabsorbed. Therefore, these data suggest that SAC
may have some eﬀect on the intestinal ﬂora;
(4) increaseofserumglucoselevelsinfemales,suggesting
that SAC induces atrophy of the pancreas and
decreases insulin secretion. Atrophy of the pancreatic
tissue has been observed only in the females admin-
istered with high dosage of SAC;Oxidative Medicine and Cellular Longevity 3
Table 1: Compositional changes in the AGE.A
Incubation time (months)
Compound 0 1 3 12 24
(mg/g dry extract)
γ-Glutamyl-S-allylcysteine 12.7 5.8 1.1 0 0
S-Allylcysteine 0.2 5.9 7.2 7.1 7.2
γ-Glutamyl-S-1-propenylcysteine 15.9 3.4 0.5 0 0
S-1-Propenylcysteine 0.5 6.7 8.1 6.5 4.4
S-Allylmercaptocysteine 0.01 0.6 1.2 1.7 1.9
ACloves were chopped into pieces (2 × 2 × 1mm) and placed into 20% ethanol (12mL/g) in a closed container and stored at room temperature. Synthesized
from [4].
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Figure 1: During the process of aging γ-glutamyl-S-allylcysteine is
converted to S-allylcysteine (SAC) by a γ-glutamyltransferase.
(5) modifying of renal (decrease blood urea nitrogen
and serum creatinine levels) and hepatic (increase
serum total cholesterol, protein, lipids, and alkaline
phosphatase levels) function in females;
(6) decrease of hematocrit, hemoglobin, mean corpus-
cular volume, mean corpuscular hemoglobin, and
mean corpuscular hemoglobin concentration in both
genders.
3.2. Pharmacokinetics. In rats, pharmacokinetics of SAC
after oral administration shows a three-phase concentration
proﬁle: two very fast phases (absorption and distribution)
followedby a slow elimination phase. For i.v.administration,
SAC pharmacokinetics presents a two-phase concentration
proﬁle: a very fast distribution phase and a slow elimina-
tion phase [19, 20]. Pharmacokinetic parameters of SAC
(100mg/kg, oral and i.v.) are shown in Table 3.
Oral bioavailability of SAC at 100mg/kg dose is 91%
[19], similar to that reported in other studies where bioavail-
ability was 103.0% in mice, 98.2% in rats, and 87.2% in dogs
[20].
In addition, a pharmacokinetic study of SAC in humans
has been performed by oral administration of garlic prepa-
ration containing this compound. The half-life of SAC
in humans after oral administration was more than 10h,
and clearance time was more than 30h [18]. These results
are similar to experimental data obtained in dogs, where
the half-life of SAC was about 10h, and clearance time
was more than 24h, albeit these data were diﬀerent from
other experimental results obtained in mice [20]. Total SAC
content in the blood of volunteers at Tmax is about 450μg
(content on Tmax, 23ng/mL plasma; body weight: 65kg;
volume of total blood: 1/3 of body weight), suggesting a high
bioavailability in humans [18].
Table 2: Toxicity of SAC in mice and rat.A
LD50 (g/kg body weight)B
Oral i.p.
Mice Male 8.89 6.91
Female 9.39 3.65
Rat Male 10.94 3.34
Female 9.50 3.34
AAdapted from [18]. B50% lethal dose of a single dose i.p.: intraperitoneal
administration.
3.3. Tissue Distribution. After oral intake, SAC is easily
absorbed in the gastrointestinal tract and can be detected
in several tissues up to 8h after dosage [19, 20]. In
rats, after a single oral dosage of SAC (50mg/kg), the
area under the plasma concentration versus the time
curve from zero to the last quantiﬁable concentration
(AUC0–t) is 169.2mgh/kg, whereas, in tissues, the high-
est peak concentration is observed in the kidney (Cmax
= 65.7mg/kg at 10min). The elimination half-life varies
among tissues; for instance, liver shows the longest T1/2 value
(2.2h) the shorted value (1.2h) was observed in the brain
(Table 4). For i.v. administration, the kidney also exhibits
the highest SAC exposure (AUC0–8h = 171.9mgh/kg),
whereas the heart shows the longest T1/2 value (2.5h)
[19].
3.4. Metabolism. N-Acetyl-SAC has been identiﬁed as a
metabolite of SAC in urine of rats, dogs, and humans
[20, 21]. Also, small amounts of SAC (less than 1%) have
been observed in urine of rats. These data suggest that the
absorbed SAC seems to be metabolized to N-acetyl-SAC
by N-acetyltransferase, which is mainly found in liver and
kidney.However,ithasbeenshownthat,whenSACisalmost
completely eliminated from the liver, it is readily retained
at a comparatively high concentration in the kidney. Thus,
it can be speculated that SAC may be transformed into N-
acetyl-SAC by N-acetyltransferase in the liver, and, then, a
portionofN-acetyl-SACmaybedeacylatedtoSACbyacylase
in kidney, followed by its reabsorption [20].4 Oxidative Medicine and Cellular Longevity
Table 3: Pharmacokinetic parameters for oral and i.v. administration of SAC in the serum of rats.A
Parameter Oral administration i.v. administration
Distribution volume (Vd) 1.2L 1.3L
Elimination half-life (T1/2β) 2.7h 2.6h
Total clearance 0.3L/h 0.3L/h
Peak concentration (Cmax) 100.1mg/L at 30min
AUC0−t value 293.5mg·h/L 322.6mg·h/L
ASynthesized from [19]. AUC0−t: area under the plasma concentration versus time curve from time zero to the last quantiﬁable concentration.
Table 4: Pharmacokinetic parameters after a single oral dose of
SAC.A
Parameter Cmax AUC0−t T1/2
Tissue (mg/kg) mg·h/kg (h)
Kidney 65.7 169.2 2.1
Liver 58.1 103.5 2.2
Heart 43.3 118.8 2.1
Spleen 43.3 100.6 1.9
Lung 35.1 94.3 1.3
Brain 26.7 70.7 1.2
ASAC dose of 50mg/kg. Adapted from [19].
Cmax: peak concentration at 10min; AUC0–t:a r e au n d e rt h ep l a s m a
concentration versus time curve from time zero to the last quantiﬁable
concentration; T1/2: elimination half-life time.
4.AntioxidantMechanismsAssociatedwith
the Protective Effect of SAC and/or AGE
Several reports have shown that AGE and SAC inhibit
the oxidative damage implicated in aging and a variety
of diseases. Derived of these works, diﬀerent antioxidant
mechanisms have been attributed to these compounds
and conﬁrmed. Figure 2 shows the antioxidant mechanism
associated with the protective eﬀects of SAC.
4.1. AGE and SAC Scavenge Reactive Oxygen Species. SAC
contains a thiol group responsible of its antioxidant capacity
because this nucleophile can easily donate its proton to an
electrophilic species, thereby neutralizing them or making
them less reactive.
SAC is the most studied compound of AGE and its
antioxidant properties have been reported in several studies.
SAC readily prevents lipid [22–26] and protein oxidation
[27] and nitration [28], supporting its antioxidant activity.
Actually, SAC is known to scavenge superoxide anion (O2
•−)
[14, 27, 29], hydrogen peroxide (H2O2)[ 22, 27, 29–31],
hydroxyl radical (•OH) [14, 23, 29, 32], and peroxynitrite
anion (ONOO−)[ 28, 29]. Medina-Campos et al. reported
that SAC scavenges hypochlorous acid (HOCl) and singlet
oxygen (1O2). Furthermore, these authors compared the
scavenging activity of SAC against reference compounds
(molecules that scavenge a speciﬁc reactive oxygen species)
through the IC50 value for each reactive species. SAC
scavenged HOCl in a similar manner than lipoic acid,
and it was more eﬃcient to scavenge 1O2 than lipoic acid
and reduced glutathione [29]. Recently, Maldonado et al.
reportedthatSACwasabletoscavenge •OHandperoxylrad-
ical (ROO•) in a concentration-dependent manner, and this
eﬀect is reduced when SAC is changed by S-propylcysteine,
suggesting that allyl group in SAC is necessary for its
scavenging activity [33]. To further support this concept, in
ourlaboratory,wehaveobserved thatallylgroup isnecessary
to preserve the scavenging activity of SAC on diﬀerent
reactive oxygen species (unpublished data).
On the other hand, AGE is known to scavenge H2O2 [22,
30]a n dO 2
•− [34, 35]. Consistently, Wei and Lau observed
ap r o t e c t i v ee ﬀect of AGE (1–8mg/mL) in endothelial
cells challenged by H2O2 or the O2
•− generator system
xantine/xanthine oxidase [36].
Besides SAC, there are other compounds in AGE exhibit-
ing antioxidant properties: (a) S-allylmercaptocysteine scav-
enges •OH and 1O2 [37]; (b) alliin scavenges •OH [38],
O2
•− [32], and H2O2 [22] and inhibits lipid peroxida-
tion [22]; (c) Nα-(1-deoxy-D-fructos-1-yl)-L-arginine scav-
enges H2O2 [8, 39] and also inhibits the Cu2+-induced
low-density lipoprotein (LDL) oxidation and peroxides
release during the coincubation of macrophages with oxi-
dized LDL [39]; (d) tetrahydro-beta-carbolines show a
strong H2O2 scavenging activity while inhibit 2,2 -azobis(2-
amidinopropane) hydrochloride-induced lipid peroxidation
and nitrite production induced by lipopolysaccharide in
murine macrophages [9, 10].
4.2. AGE and SAC Induce Antioxidant Enzymes and Nrf2
Factor. Hsu et al. evaluated the eﬀect of SAC (1g/L in
drinking water for 4 weeks) on the activity of catalase
and glutathione peroxidase in Balb/cA mice. After 4 weeks
of treatment, SAC increased glutathione levels in kidney
and liver when compared with controls. Moreover, SAC
enhanced catalase and glutathione peroxidase activities in
kidney and liver [40]. These data suggest that SAC could be
acting by recruiting diﬀerent mechanisms, including radical
scavenging and induction of antioxidant enzymes.
Lawal and Ellis reported that AGE prevented death in
Cd-treated 1321N1 and HEK293 cells, due to cell AGE
reduced Cd-induced lipid peroxidation and LDH leakage,
increased GSH levels, expression of the protective enzyme
NAD(P)H:quinone oxidoreductase, and the accumulation of
the transcription factor Nrf2. The authors suggest that AGE
could be beneﬁcial in Cd-induced toxicity, and this protec-
tion appears to be mediated via induction of cytoprotective
enzymes in a Nrf2-dependent manner. This indicates the
AGE potential use as a chemoprevention strategy for Cd
toxicity [41].Oxidative Medicine and Cellular Longevity 5
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Figure 2: Antioxidant mechanism associated to S-allylcysteine (SAC). SAC can scavenge superoxide anion (O2
•−), hydrogen peroxide
(H2O2), hydroxyl radical (OH•), peroxynitrite radical (ONOO−), and peroxyl radical (LOO•)p r o d u c e di nn e u r o n a lc e l l s ,a sw e l la s
hypochlorous acid (HOCl) and singlet oxygen (1O2) produced in microglial cells (blue lines). Moreover, SAC also exhibits chelating
properties on Fe2+ and Cu2+ ions (red line), hence avoiding Fenton reaction. SAC also inhibits NF-kB translocation into the nucleus (green
line), thus preventing apoptotic signaling. COX-2: cyclooxygenase-2, NOX: NADPH oxidase, nNOS: neuronal nitric oxide synthase, SOD:
superoxide dismutase, XO: xanthine oxidase.
Kalayarasan et al. reported that SAC (100mg/kg, i.p. for
3 days) is also able to activate Nrf2 factor in hepatocytes
of Wistar rats exposed to chromium [42]. The transcrip-
tion factor Nrf2 (nuclear factor-E2-related factor 2) is
the guardian of redox homeostasis as it regulates basal
and inducible expression of antioxidant and cytoprotective
genes, providing the level of protection required for normal
cellular activities and against various oxidative stress-related
pathologies, including ischemic stroke [43–45]. Lee et al.
reportedthemajorfunctionalcategoriesofgenesresponsible
for conferring protection against oxidative stress or inﬂam-
mation [46]. These genes codify for detoxifying enzymes,
antioxidant proteins, NADPH-producing proteins, growth
factors, defense/immune/inﬂammation related proteins, and
signaling proteins; thus, the activation of Nrf2/ARE (antioxi-
dantresponseelement)pathwaycouldstimulateasynergistic
protective eﬀect [47].
Nrf2 is highly expressed in detoxifying organs—such
as liver and kidney—and other organs commonly exposed
to external environmental conditions—including the skin,
lung, and digestive tract—[48], whereas in the brain its levels
are low [49].
To date, there is no available information on Nrf2
induction by AGE or SAC in the brain. Here, we show that
SAC administration (100mg/Kg for 5 consecutive days) is
able to activate Nrf2 factor in homogenates of cerebral cortex
at 24h (Figure 3). Although the precise mechanism through
which SAC is able to evoke this eﬀect in cerebral cortex
still remains unclear, a mechanistic proposal is shown in the
Figure 4.
4.3. AGE and SAC Inhibit Prooxidant Enzymes
4.3.1. Nitric Oxide Synthase (NOS). NOS family is formed
by three isoforms: neuronal NOS (nNOS) and endothelial
NOS (eNOS) are constitutively expressed and require the
formationofaCa2+-calmodulincomplexfortheiractivation.
The third isoform, inducible NOS (iNOS), exerts its activity
in a Ca2+-independent manner [50]. In the presence of O2,
these enzymes catalyze the conversion of L-arginine to L-
citrulline plus nitric oxide (NO). Despite increased levels
of NO have been involved in degenerative events, NO is
also a well-known small molecule that acts as a second6 Oxidative Medicine and Cellular Longevity
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Figure 3: S-Allylcysteine (SAC) induces the activation of the tran-
scription factor nuclear factor-E2-related factor 2 (Nrf2) in cerebral
cortex. Animals received SAC 100mg/kg every day for 5 days.
Quantiﬁcation was made by ELISA at 450nm in nuclear extracts
from frontal cortex of rats at 24h after the last administration of
SAC. Values are expressed as mean ± SEM. n = 4-5. aP < 0.0244
versus control group. Student’s t-test. OD: optical density.
messenger in cellular signaling and in a large variety of
diverse physiological processes, including neurotransmis-
sion, vascular relaxation, blood pressure regulation, defense
mechanisms, and immune regulation [51]. Therefore, a
dysregulation of NO concentrations compromises the cell
survival mechanisms.
SACisknowntoinhibitNOproductioninLPS/cytokine-
stimulated macrophages and hepatocytes by suppression of
iNOS gene expression [14]. A SAC-induced inhibition of
NO production may be related to its ability to decrease NF-
κBa c t i v a t i o n[ 13, 52], thus leading to cell protection. On
the other hand, reports in vivo indicate that AGE increases
NO levels through the stimulation of the constitutive NOS
isoforms, but not iNOS [15]; however, this mechanism has
not been elucidated yet. Altogether, these data suggest that
AGE and SAC could be useful in diseases associated with
oxidative stress involving dysfunction in NO production.
4.3.2. Xanthine Oxidase (XO). XO and xanthine dehydroge-
nase (XDH) are interconvertible forms, and both are mem-
bers of the molybdenum hydroxylase ﬂavoprotein family;
they carry out similar reactions in the purine catabolism
in mammals, which are often referred as xanthine oxi-
doreductase activity. The interconversion from XDH to XO
can be either reversible by sulphide reagents (oxidation of
important protein thiol group) or irreversible by proteol-
ysis (calcium-dependent proteases) [53]. In particular, XO
catalyzes the oxidation of hypoxanthine to xanthine and
xanthine to uric acid with the concomitant O2 reduction
by a single electron. In turn, XDH catalyzes the same
reaction with the reduction of NAD+ by direct two-electron
reduction. O2 reduction yields O2
•− and H2O2 as secondary
products [54]. O2
•− generated can then react with NO to
generate ONOO−, a strong oxidant capable of damage to
proteins, lipids, and DNA.
Demirkaya et al. reported that AGE administration
(3mL/kg during 6 weeks, starting 1 week before doxorubi-
cin treatment) decreased XO activity in a model of
doxorubicin-induced cardiotoxicity. However, the protective
eﬀect observed in this model was not associated with the
decrease in XO activity, but to the ability of AGE to increase
the levels of some antioxidant enzymes, while decreasing
lipid peroxidation [55].
4.3.3. NADPH Oxidase. NADPH oxidase is an enzymatic
complex located mainly in the plasmatic membrane of spe-
ciﬁc granules of phagocytic leukocytes, such as neutrophils
and macrophages. It catalyzes the formation of O2
•−,w h i c h
together with other oxidant species, is produced to kill
ingested microorganism (reviewed in [56]). NADPH oxidase
overactivation has been related to diﬀerent pathophysio-
logical events, including renal injury [57], hypertension,
atherosclerosis, angiogenesis, and ischemia/reperfusion [56].
Cruzetal.reportedaprotectiveeﬀectofSAC(200mg/kg,
i.p.) and AGE (1.2mL/kg i.p.) administrated every day for
30 days, in 5/6 nephrectomized rats, a model of renal injury
and hypertension. In this work, the protective eﬀect exerted
by these compounds was associated with their antioxidant
properties andtheirabilitytodecreasegp91phox andgp22phox
levels [58]. However, the mechanism by which SAC and
AGE decrease the abundance of gp91phox and gp22phox is
unclear. In animals, gp91phox is the catalytic subunit of
NADPH oxidase, whereas gp22phox is a membrane protein
that forms a heterodimer with gp91phox to produce O2
•−.I t
is known that NADPH oxidase activation is implicated in the
pathogenesis of several renal diseases due to its capacity to
produce O2
•−, and its inhibition may be useful to ameliorate
and delay the progression of renal injury [57].
4.3.4. Cyclooxygenase (COX). COX catalyzes the rate-
limiting step in the synthesis of prostaglandins and throm-
boxanes from arachidonic acid [59]. There are two main
COX isoforms: COX-1, a constitutive enzyme expressed in
many tissues with functions such as gastric mucose protec-
tion and regulation of vascular tone [60]. In contrast, the
COX-2 isoform is an inducible enzyme primarily associated
with inﬂammatory processes [59, 60]. Several stimuli induce
COX-2, including bacterial lipopolysaccharide, interleukin-1
(IL-1),IL-2,andtumornecrosisfactor(TNF-α)[60].COX-2
activity has also been associated with oxidative stress due to
its capacity to produce O2
•− from O2.
Col´ ın-Gonz´ alezetal.reportedtheeﬀectofAGEonCOX-
2 protein levels and activity in a model of cerebral ischemia.
They found that AGE administration (1.2mL/Kg i.p.,o n s e t
of reperfusion) exerted a neuroprotective eﬀect attributable
to its ability to decrease the ischemia-induced increase of 8-
hydroxy-2-deoxyguanosine (a marker of oxidative damage
to DNA) and TNF-α levels (an inﬂammation marker).
Moreover, AGE decreased COX-2 protein expression and
activity, although its mechanism of action remains unclear
[61].
Noteworthy, only a few studies have paid attention to the
eﬀects of AGE and SAC on the main prooxidant enzymes
(XO, NADPH oxidase, or COX), so the mechanisms involved
in the possible inhibitory actions of these compounds have
been not elucidated yet.Oxidative Medicine and Cellular Longevity 7
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4.4. Chelating Eﬀect of SAC and AGE. Divalent metals
(zinc, iron, copper, cobalt, manganese) are involved in a
considerable number of physiological processes. However,
some of these metals (mostly iron and copper) are involved
in the generation of reactive oxygen radicals. A patholog-
ical increase in iron or calcium levels has been related
with oxidative stress and mitochondrial damage, further
leading to neuronal death. Thus, neurodegeneration can
be determined by alterations in ionic homoeostasis and/or
changes in prooxidative-antioxidant equilibrium, two con-
ditions that are constantly modiﬁed in brain cells (reviewed
in [62]). Moreover, the observations that iron induces
aggregation of α-synuclein and β-amyloid (Aβ)p e p t i d e st o
form toxic aggregates reinforce its critical role in oxidative
stress-induced pathogenesis in neurodegeneration (reviewed
in [63]). Furthermore, Fenton and Haber-Weiss reactions
(Figure 5) are two mechanisms through which free iron
or copper produce reactive oxygen species—particularly
•OH—to further lead to oxidative degradation of lipids, pro-
teins, and ADN [64–66]. In this regard, it has been reported
that the brains of Alzheimer’s patients have increased levels
of iron, zinc, and copper when compared to control patients
[65, 67, 68], whereas the brains of Parkinson’s patients show
a marked increase in iron and zinc levels [65, 68].
On the other hand, it has been reported that the
interaction between Cu2+ and Aβ produces Aβ-Cu+ and
H2O2, and this monovalent form of copper catalyzes the
oxidation of Aβ and free radicals production through the
Fenton reaction [65, 66, 69] as follows:
Cu2+ +Aβ −→ Aβ-Cu+ +H 2O2
−→ Aβ-Cu2+ +
•OH+OH
− (1)
Altogether, these data support the concept that a combi-
nation of free metal chelation and antioxidant therapies may
constitute a valuable approach for neuroprotection.8 Oxidative Medicine and Cellular Longevity
Fe3+ +O 2
•− Fe2+ +O 2
Fe2+ +H 2O2
O2
•− +H 2O2
Fe3+ + •O H+O H −
O2 + •OH + OH−
Fenton reaction
Haber-Weiss reaction
Figure 5: The known ways in which iron is directly involved in
the generation of reactive oxygen species. The production of these
species is potentially harmful for several cell types and tissues.
Adapted from [66].
Dairam et al. found that SAC (30μg/mL) possesses the
property of chelating Fe2+ and Fe3+ in a concentration-
dependent manner [70]. Moreover, it has been shown that
AGE [34]a n dS A C[ 71] are able to inhibit Cu2+-induced
LDL oxidation, an eﬀect associated to its ability to chelate
Cu2+. In addition, Dillon et al. using a xanthine-XO assay
and CuSO4 as inhibitor of XO reported that AGE chelates
Cu2+ and restores the activity of XO [72].
5. Neuroprotective Effects of AGE
Technology is increasing exponentially impacting on every
aspect of life, improving research, diagnosis, equipment,
and procedures in medicine. As a result, life expectancy is
increasing, and the population is ageing (in 2007, the overall
life expectancy at birth in the US was 77.9 years, representing
anincrease of 0.2 yearsfromthatreported in 2006) [73].Asa
consequence,theincidenceofneurodegenerativediseaseshas
been increased [74, 75] constituting a global problem that
willcauseprofoundeconomicalandsocialchallenges.Nowa-
days, there are no disease-modifying therapies designed for
these disorders, so an intense amount of research is justiﬁed.
Oxidative stress is widely implicated in the develop-
ment of neurodegenerative disorders such as AD, Stroke,
Parkinson’s disease, and Huntington’s disease, among others
[76]. Therefore, an increasing number of investigations are
expected to appear in a near future studying the eﬀects
of AGE and SAC in the central nervous system, probably
validating these agents as useful therapeutic strategies.
5.1. Neurotrophic Activity of AGE. The neurotrophic activity
of AGE was revealed in a primary culture of fetal rat
hippocampal neurons. In this study, the addition of AGE
signiﬁcantly promoted neuronal survival and the num-
ber of branching points per axon [77]. Later on, the
neurotrophic molecular mechanisms of AGE were studied
through the screening of genes diﬀerentially expressed after
the addition of AGE (0.67%) to primary cultured rat fetal
hippocampal neurons. Quantitative RT-PCR showed that
α2-microglobulin-related protein (α2MRP) mRNA levels
were remarkably increased at 24h after incubation with
AGE [78]. α2MRP is a member of the acute phase proteins,
molecules whose concentrations increase or decrease in
response to inﬂammation, tissue damage, and maintenance
of cell homeostasis [79]. This ﬁnding indicates that AGE may
directly or indirectly activates the expression of important
genes for neuronal survival, an eﬀect that could be relevant
for the design of pharmacological interventions in neurode-
generative disorders.
5.2. Attenuation of Ischemic Brain Damage by AGE. In the
US, cerebral ischemia is the third leading cause of death
and the leading cause of disability. Brain injury following
ischemia results in the activation of a series of biochemical
events eventually leading to neuronal death. Despite recent
medical and surgical advances, we are still unable to prevent
acute ischemic brain damage, so the development of eﬀective
neuroprotective methods is crucial.
The eﬀects of AGE on brain ischemia have been evalu-
ated using diﬀerent administration schemes in the middle
cerebral artery occlusion paradigm: (1) AGE (0.5mL/Kg
i.p.) applied 30min before the onset of ischemia (1h
ischemia/72h reperfusion) decreased edema formation [80];
(2) AGE (1.2mL/Kg i.p.) applied at the beginning of
reperfusion (2h ischemia/2h reperfusion) decreased infarct
area, 3-nytrotirosyne levels, and prevented the decrease in
antioxidant enzymes (glutathione peroxidase and superox-
ide dismutase) [81]; (3) AGE (1.2mL/Kg i.p.)a p p l i e da t
the beginning of reperfusion (1h ischemia/24h reperfu-
sion) diminished infarct area, neuronal deﬁcit, histological
alterations, 8-hydroxy-deoxyguanosine, TNF-α, and COX-
2l e v e l s[ 61]. All the above-mentioned ﬁndings show that
the complex physiopathological mechanisms leading to
neuronal injury in cerebral stroke can be modiﬁed by
AGE treatment at diﬀerent doses, administration sched-
ules, and ischemia/reperfusion times, thus emphasizing its
broad spectrum of therapeutic applications. However, the
protective eﬀect exerted by AGE in this model may be
primarily associated to the prevention of oxidative stress and
inﬂammatory responses.
5.3. Antiageing Eﬀect of AGE. Oxidative stress and immune
dysfunctioninbiologicalsystemsareamongthemostimpor-
tant causes of ageing [82, 83]. The senescence-accelerated
mouse is a genetic murine model for studying ageing and
spontaneous senescence, and these animals show a short life
span and exhibit several signs of senescence in early age
(impairment of learning and memory performance, neuro-
chemical changes, etc.) [84]. Chronic oral administration
(2 month) of AGE-enriched food (2% w/w) to senescence-
accelerated mouse (1) prevented skin glossiness, coarseness,
and hair loss; (2) increased survival ratio; (3) improved the
memory acquisition deﬁcit; (4) avoided the decrease of brain
weight and the atrophy of the frontal portion of the brain
[85–87].
On the other hand, Zhang et al. raised the question on
whether AGE could have any eﬀect as immunomodulator
in the central nervous system. To answer this question, they
used an oral administration of AGE (2% w/w) in senescence-
accelerated mouse and found that this compound increased
immune responses, suggesting that AGE may also improve
age-associated decline in the immune system. Shortly there-
after, they also observed the eﬀect of AGE in thymec-
tomized mice, a model of immunodeﬁciency and deterio-
ration of learning performance. AGE treatment prevented
the reduction of antibody production responses, improved
the deterioration of learning behavior, and restored the
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homovanillic acid, and cholineacetyltransferase activity in
the hypothalamus. These data suggest that AGE has the
capability of reverting thymectomy-induced alterations to
normal levels [88].
Clinical studies have demonstrated that brain lesions
in Alzheimer’s patients may be associated with abnormal
immune reactions [89]. Thus, AGE has also been used in
Alzheimer animal models. In 2006, Chauhan investigated
the anti-inﬂammatory eﬀects of dietary AGE (2% w/w) in
an Alzheimer’s transgenic model harboring Swedish double
mutation (KM670/671NL; Tg2576). The Tg2576 brains
t r e a t e dw i t hA G Es h o w e dr e d u c t i o n si nT N F - α levels accom-
panied by reductions in IL-1β level, and positive plaque-
associated microglia, thereby demonstrating a possible anti-
inﬂammatory eﬀect of this compound [90].
AGE contains multiple ingredients with neurotrophic
activity that may directly or indirectly prevent the ischemic
damage and the age-related morphological changes. There-
fore, further studies, including isolation, puriﬁcation, and
identiﬁcation of its speciﬁc compounds and the mechanisms
involved, are needed.
6. NeuroprotectiveEffects of SAC
SAC has been used in several works in order to ﬁnd eﬀective,
therapeutic, and preventive strategies for intervention in
neurodegenerative diseases.
6.1. Neurotrophic Eﬀect of SAC. Moriguchi et al. reported
the positive actions of garlic compounds (including SAC)
with a thioallyl group in rat hippocampal neurons culture.
In this work, SAC increased survival and axonal branching
from neurons. Based on these ﬁndings, this group suggested
thatthioallylgroupisessentialforneurotrophicactivity[91].
ThesedatasuggestthatSACisacompoundthatnotonlyacts
as an antioxidant agent but also as a neurotrophic molecule.
6.2. SAC in Experimental Models of Alzheimer’s Disease (AD).
AD is a devastating neurodegenerative disorder which causes
progressive loss of cognitive abilities, the accumulation
of Aβ deposits in the basal forebrain, hippocampus, and
cortex, together with oxidative stress, have been consistently
implicated in the pathogenesis of this disorder [92]. In
this regard, the design of a treatment with antioxidant
and/or antiamyloidogenic properties represents an approach
of considerable therapeutic value for the prevention of the
disease progression.
The eﬀect of SAC on PC12 cells exposed to Aβ(25–35) has
also been evaluated. SAC suppressed the generation of ROS;
attenuated caspase-3 activation, DNA fragmentation, and
PARP cleavage eventually protecting against Aβ-induced cell
death [93, 94]. Moreover, SAC attenuated cell death induced
by Aβ in organotypic hippocampal culture and cultured hip-
pocampal neurons in a concentration-dependent manner,
an eﬀect apparently mediated by the caspase-12-dependent
pathway [95–97].
On the other hand, some studies have shown that AD
patients exhibit an overstimulation of the N-methyl-D-
aspartatereceptorinsometimepointsofthediseaseprogress
[98]. In order to reproduce this state, Aβ and ibotenic acid (a
potent N-methyl-D-aspartate agonist) administrations have
been used in organotypic hippocampal cultures resulting
in a time-dependent neuronal damage, a feature that SAC
administration (10 and 100mM) signiﬁcantly attenuated in
the CA3 area [95].
AD involves misfolding and aggregation of proteins
which increased endoplasmic reticulum stress [99]. Tuni-
camycin, an inhibitor of N-glycosylation in endoplasmic
reticulum, reproduces some severe neurological alterations
in animals (resembling neurological disorders) through the
induction of endoplasmic reticulum stress. The role of
SAC (10−8–10−5M) on tunicamycin-mediated cell death
was investigated in PC12 cells and hippocampal neurons,
showing a selective neuroprotective eﬀect on the caspase-12-
dependent apoptotic pathway [96, 100]. In another work,
Aβ plus tunicamycin-induced neurotoxicity was assessed
in organotypic hippocampal slice cultures, where SAC
(100μM) improved cell viability in area CA3 and dentate
gyrus. Simultaneously, SAC reversed calpain activity as well
as the active forms of caspase-12 and caspase-3, without
changing the increased levels of endoplasmic reticulum
chaperones (GRP94 and −78) or C/EBP homologous pro-
tein. The authors suggest that SAC could either directly
interact with calpain or alter the environment in the vicinity
of the endoplasmic reticulum lumen without aﬀecting
unfolded protein responses or the C/EBP homologous
protein-mediated signaling pathway induced by Aβ plus
tunicamycin [101].
In addition, the protective eﬀect of SAC in Aβ toxicity
could not be only related to its antioxidant activity as Gupta
and Rao investigated the eﬀect of SAC on Aβ aggregation in
vitro. SAC (10–50M) not only inhibited Aβ ﬁ b r i l l a t i o ni na
dose-dependent manner and disestablished preformed Aβ-
peptideﬁbrils,butalsoboundtoAβ ﬁbrils.Inadocking pro-
tocol,thesitesuitableforaccommodatingSACwasidentiﬁed
around the Aβ40 structure. It was mentioned that SAC could
interact with the positively charged Gln15-Lys16 segment.
In fact, binding could be induced either by hydrophobic
interactions between allyl chain and hydrophobic regions of
Aβ (Phe 19 and Val 12), or by the H-bond between the -OH
group of the carboxylic group of SAC and donator/acceptor
groups of Aβ [102].
Since there is a possibility that AD results from inheri-
tance of an autosomal dominant mutation in the amyloid
precursor protein, the introduction of mutant amyloid
precursor protein genes into suitable mouse pronuclei is
used to build transgenic mouse models of AD. These
mutant amyloid precursor protein transgenic models exhibit
the progressive Aβ neuritic plaques formation, dystrophic
neuritis, and neuroinﬂammation [103]. Interestingly, the
dietaryadministrationofSAC(20mg/kgfor4month)inone
of these transgenic models decreased Aβ load, IL-1β reactive
plaque-associated microglia, Tau2 reactivity, and GSK-3β
protein, showing an antiamyloidogenic, anti-inﬂammatory,
and antitangle activity (via GSK-3 β)[ 90].10 Oxidative Medicine and Cellular Longevity
Intracerebroventricular injection of streptozotocin to
mice impairs brain biochemistry, cerebral glucose, energy
metabolism, cholinergic transmission, and increases gener-
ation of free radicals, further leading to cognitive deﬁcits;
these eﬀects are similar to sporadic dementia in humans.
Pretreatment with SAC (30mg/kg every day for 15 days)
in intracerebroventricular streptozotocin-infused mice ame-
liorated hippocampal neuronal abnormalities, prevented the
cognitive and neurobehavioral impairments, restored levels
of reduced glutathione and its dependent enzymes (glu-
tathione peroxidase and glutathione reductase), diminished
lipid peroxidation, DNA fragmentation, and p53 levels, and
increased Bcl2 levels [104].
Finally, SAC (1g/L for 15 weeks, added to the drinking
water) was tested in D-galactose-injected mice. D-Galactose
induces AD-like pathological changes in the brain, including
increased reactive oxygen species, decreased antioxidant
enzyme activity, and enhanced Aβ-peptide expression. SAC
decreased the brain levels of Aβ1–40 and Aβ1–42,l o w e r e d
amyloid precursor protein level and BACE1 expressions
and activities (both of them being factors responsible
for Aβ accumulation and AD progression), retained PKC
activity and expression of PKC-α and PKC-γ,l o w e r e dA β
accumulation, reduced the levels of advanced glycation
end products (carboxymethyllysine, pentosidine), lowered
aldose reductase activity and expression (an enzyme that
facilitates the production of sorbitol and fructose, which in
turn promote advanced glycation end products formation
and glycative stress), and displayed antioxidant protection
(evidenced by increased reduced glutathione content and
glutathione peroxidase, superoxide dismutase, and catalase
activities, accompanied by decreased levels of malondialde-
hyde, reactive oxygen species, and protein carbonyls) [105].
The aforementioned evidence serves to suggest that SAC
might prevent the progression of AD by multiple mech-
anisms: antioxidant, antiamyloidogenic, anti-inﬂammatory,
antitangle, and antiglycative activities (Figure 6). However,
further studies are essential to determine if SAC is capable
of displaying all these proprieties in humans.
6.3. SAC in Ischemic Brain Damage. The eﬀect of SAC in
ischemic brain damage was tested at 100, 300, and 600mg/kg
i.p. applied 30min prior the onset of ischemia in rats. SAC
(300mg/Kg) induced signiﬁcant reduction of the infarct
volume, water content, oxidative stress and improvement
in motor performance and memory impairment [23, 80].
Moreover, in a two-vessel occlusion model in gerbils, the
oral and i.p. administration of SAC 300mg/kg increased the
number of surviving cells/mm2 of CA1 region [106].
Hypertension is recognized as the most important risk
factor for the development of ischemic cerebral infarction
in humans [107]. Kim et al. evaluated the eﬀect of SAC
in stroke-prone spontaneously hypertensive rats, demon-
strating that SAC (5%, 28 day of diet period) reduced
mortality and the overall stroke-related behavioral score
[108]. In another work, the same authors showed that
SAC (300mg/Kg) reduced the size of infarct area after
2h occlusion and 22h reperfusion, prevented neuronal cell
death in CA1 region and inhibited the activity of ERK
induced by focal ischemia in a middle cerebral artery
occlusion model in gerbils, while in vitro exerted scavenging
activity on peroxynitrite [28].
Additionally,ithasbeenreportedthatthepositiveactions
of SAC seen in the cerebral ischemia-induced damage to
the hippocampus may be due to the possible modulation
of mitochondrial dysfunctions. SAC 300mg/kg i.p. adminis-
teredtwice(15minpreocclusionand2hpostocclusionatthe
time of reperfusion) in the middle cerebral artery occlusion
model in rats, produced a signiﬁcant decrease in mitochon-
drial lipid peroxidation, protein carbonyl levels, cytochrome
c release, and intracellular H2O2 levels. Furthermore, SAC
also restored the status of mitochondrial glutathione and
glucose 6-phosphate dehydrogenase, ATP content, and the
activityofmitochondrialrespiratorycomplexes(I-IV)[109].
Inconclusion,theprotectiveeﬀectsofSAConbrainischemic
damage may be associated with the decrease of oxidative
stress and the modulation of mitochondrial dysfunctions.
6.4. SAC in Experimental Models of Huntington’s Disease.
Huntington’s disease is an autosomal dominant neurode-
generative disorder characterized by the gradual and pro-
gressive loss of neurons, predominantly in the striatum. It
is caused by a mutation in the huntingtin gen. Its main
clinicalmanifestationsarechorea,cognitiveimpairment,and
psychiatric disorders, most of them related to striatal and
cortical atrophy. Nowadays, there is no treatment to prevent
or reduce the morphological and functional alterations seen
in the brains of Huntington’s patients. For this reason, it is
imperative to look for pharmacological strategies to improve
the quality of life of these patients [110].
SAC has been used in two animal models of Hunt-
ington’s disease: 3-nitropropionic acid and quinolinic acid.
SAC (300mg/kg i.p.) administration to rats infused with
3-nitropropionic acid prevented behavioral alterations,
increased manganese and copper/zinc superoxide dismutase
activities, and decreased lipid peroxidation and mitochon-
drialdysfunction[111].Simultaneously,SAC(0.75mM)also
decreased lipid peroxidation and mitochondrial dysfunction
induced by 3-nitropropionic acid in synaptosomal fractions
[112].
On the other hand, it has been reported that SAC bonds
Fe2+ and Fe3+, preventing the redox cycling of iron, and
consequently, the quinolinic acid induced-lipid peroxidation
[70]. Alternatively, the eﬀect of SAC was evaluated in a
combinedmodelofexcitotoxicity/energydeﬁcitproducedby
the coadministration of quinolinate and 3-nitropropionate
acid in brain synaptosomal membranes. SAC abolished the
quinolinic acid plus 3-nitropropionate acid-induced lipid
peroxidation [113,114]. Theprotectiveeﬀectof SACin these
models has been attributed to its ability to preserve the cell
redox status through its antioxidant properties and probably
to its iron-binding properties.
6.5. SAC in Experimental Models of Parkinson’s Disease.
Parkinson’s disease is characterized by progressive degen-
eration of dopaminergic neurons in the substantia nigraOxidative Medicine and Cellular Longevity 11
Microglia
Inﬂammatory
process
Neuron
IL-1β, TNF-α
Glucose
AR
Sorbitol
Fructose
AGEs
(CML)
ROS
Oxidative
damage
ROS
Calpain
Caspases
activation
(12, 3)
Oxidative
damage
ER
Aβ aggregate
Aβ aggregate
Aβ peptide
BACE
APP
Neuron
tau-2   
Phosphorylated
Aβ peptide
1
2
3
4
5
Nucleus Cytoplasm
PKC α, γ +
SAC
S
O
OH
NH2
SAC
S
O
OH
NH2
SAC
S
O
OH
NH2
SAC
S
O
OH
NH2
SAC
S
O
OH
NH2
Ca2+
GSK-3β
Figure 6: S-allylcysteine (SAC) prevents the progression of Alzheimer’s disease (AD) by multiple mechanisms: (1) antioxidant,S A C
scavenges free radicals and oxidant specie (direct antioxidant) and restores glutathione peroxidase, glutathione reductase, and superoxide
dismutase levels (indirect antioxidant). Consequently, SAC diminishes lipid peroxidation, DNA fragmentation, protein oxidation, and
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calpain and the caspase-12-dependent pathway, which altogether decrease the cell death; (2) antiamyloidogenic, SAC decreases Aβ formation
and/or increases Aβ clearance. SAC lowers amyloid precursor protein (APP) mRNA expression, BACE (β-site APP cleavage enzyme 1)
expression and activity and restores PKC activity under AD-like condition, which beneﬁts APP cleavage and decreases the available APP
for Aβ. In addition, SAC can bind to Aβ-inhibiting Aβ ﬁbrillation and destabilizing preformed Aβ-peptide ﬁbrils; (3) anti-inﬂammatory,
SAC decreases IL-1β and TNF-α levels and IL-1β-positive plaque-associated microglia; (4) antitangle, SAC reduces tau2 reactivity and
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(AGEs) formation, such as carboxymethyllysine (CML) and pentosidine, decreasing glycative stress.
pars compacta, with the concomitant formation of intra-
neuronal ﬁbrillar inclusions (Lewy bodies) and depletion of
noradrenaline and serotonin in other brain stem nuclei. In
addition, it shows oxidative tissue damage and bioenergetic
deﬁcits [115].
1-Methyl-4-phenylpyridinium (MPP+) is the stable
metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri
dine, and it causes nigrostriatal dopaminergic neurotoxicity,
which in turn has been the most widely used model of
Parkinson’s disease. Rojas et al. reported the neuroprotective
eﬀects of SAC against the oxidative stress induced by MPP+
in the mouse striatum. They found that SAC protected
dopamine levels, improved hypolocomotion, decreased
ROS production and lipid peroxidation, and increased
Cu,Zn superoxide dismutase activity in mice injected with
MPP+ [116]. Another Parkinsonian model is produced by
6-hydroxydopamine (6-OHDA). In this model, SAC blocked
the oxidative damage, prevented dopamine depletion, and
returned behavioral performanceto basal levels in rats [117].
The protective actions of SAC observed in these models were
mainly attributable to its antioxidant activity.
7.AGEinHumans
Altogether, the data presented in this paper clearly shows
that AGE and SAC exert antioxidant activity in a variety
of experimental models. Of course, these data could be
relevant for humans. Indeed, some groups have reported
protective eﬀects after chronic administration of AGE to
patients with cardiovascular disease and the mechanisms of
protection have been associated with the reduction of mul-
tiple cardiovascular risk factors, including blood pressure,12 Oxidative Medicine and Cellular Longevity
cholesterol, platelet aggregation and adhesion, and vascular
calciﬁcation (reviewed in [118, 119]). However, only a few
works have been performed in humans bringing attention to
the antioxidant eﬀects of AGE, and these are reviewed here.
7.1. Eﬀect of AGE in Atherosclerotic Patients. Cardiovascu-
lar mortality is frequently associated with atherosclerosis,
a chronic multifactorial disease and a leading cause of
death worldwide. Lipid peroxidation and LDLs oxidation,
produced by free radicals and end-aldehyde products of
lipid hydroperoxide breakdown, play an important role in
atherosclerosis. Munday et al. reported that LDLs isolated
from subjects receiving 2.4g of AGE daily for 7 days are
more resistant to oxidation than those LDL isolated from
subjects receiving no supplementation, suggesting that AGE
could be useful in preventing the oxidative stress induced
in atherosclerotic disease [120]. Later on, Durak et al.
demonstrated that oxidative stress is present in atheroscle-
rotic patients and that the consumption of AGE (1mL/kg
daily; 10g garlic/day) for 6 months decreased plasma and
erythrocyte malondialdehyde levels, with no changes in
superoxide dismutase and glutathione peroxidase activities
[121].
Currently, there is not enough evidence to determine
whether antioxidants can reduce atherogenesis or not;
however, it is conceivable that combined antioxidant (AGE)
and serum cholesterol-lowering therapies may be useful in
reducing the progression of atherosclerosis in humans.
7.2. Eﬀect of AGE in Sickle Cell Anemia Patients. Sickle cell
disease is one of the most prevalent hereditary disorders with
prominent morbidity and mortality. Clinical manifestations
are associated to hemolytic processes leading to severe
anemia. It has been reported that oxidative stress plays a
signiﬁcant role in the pathophysiology of sickle cell disease,
since it contributes to the sickling process with formation of
Heinz bodies that are aggregates of insoluble hemochromes
[122].
Takasu et al. reported that AGE (5mL/day for 4 weeks)
diminished the number of Heinz bodies in sickle cell anemia
patients and suggested that AGE may be evaluated as a
potential therapeutic agent to ameliorate complications of
sickle cell anemia [123].
7.3.EﬀectofAGEinSmokingIndividuals. F2-isoprostanesare
afamilyofprostaglandinF2 isomersthatareproducedinvivo
by cyclooxygenase-independent free radical peroxidation of
arachidonic acid and are released to plasma in response to
cellular activation. Hence, quantiﬁcation of F2-isoprotanes
in plasma and urine is a sensitive and speciﬁc indicator of
lipid peroxidation in vivo. Smokers are exposed to increased
oxidative stress and show increased levels of F2-isoprotanes
in plasma and urine. Dillon et al. found that dietary
supplementation with AGE (5mL in a small volume of fruit
juice) for 14 days reduced plasma and urinary levels of F2-
isoprostane 8-iso-prostaglandin F2α in smokers, suggesting
that dietary consumption of AGE may be useful in reducing
oxidative stress in humans [17].
8. FinalRemarks
In summary, the evidence presented in this paper supports
the many beneﬁcial health eﬀects attributable to AGE and
SAC, as they are able to reduce the risk of stroke and neu-
rodegenerative damage. Moreover, given that SAC is a potent
antioxidant agent, a water soluble compound less toxic than
other antioxidants, easily absorbed in the gastrointestinal
tract, and rapidly detected in several tissues (kidney, liver,
lung, brain), it has been suggested that this compound
might exhibit prophylactic properties at a clinical level.
However, further investigations are still needed to elucidate
thepreciseprotectivemechanismsexertedbythisantioxidant
in several toxic paradigms. Finally, further studies in humans
are also necessary to support the clinical use of SAC as a
drug to prevent the oxidative damage observed in chronic
degenerative disorders.
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